GlassScriptPhysician profile
Stephan N Schott
NPI 1053308882
$756.50
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $192.16 | 2019-2020 | |
| Pfizer INC. | $97.10 | 2019-2020 | |
| Novo Nordisk INC | $58.10 | 2020 | |
| Amgen INC. | $49.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.49 | 2019 | |
| Eisai INC. | $29.72 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.75 | 2019-2020 | |
| Antares Pharma, INC. | $28.18 | 2019-2020 | |
| Amarin Pharma, INC. | $24.63 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $23.45 | 2019 | |
| Lilly USA, LLC | $20.24 | 2020 | |
| Glaxosmithkline, LLC. | $16.63 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $15.01 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Schott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.